Project Grant R01HD113199
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$2.3M
Funding Federal Agency
National Institute on Drug Abuse
Awarding Federal Agency
National Institute of Child Health and Human Development
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded Magee-Womens Research Institute and Foundation a $3,092,159 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to conduct a multimodal analysis of gestational health and placental injury in opioid-affected pregnancies. The goal is to investigate the direct impact of illicit and prescription opioids on placental development, differentiation, and function, focusing on the critical syncytiotrophoblast and...
This Project Grant award of $3,011,183 from the National Institute on Drug Abuse (NIDA), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), supports research to investigate the effects of maternal opioid use disorder (OUD) on the placenta-brain axis and associated neurocognitive outcomes in offspring. The University of Kentucky Research Foundation, the prime awardee, will utilize a systems biology approach to integrate phenotypic, functional, and genomic data from the...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to:
Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples....
This $2,267,819 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Abuse and Addiction Research Programs) will fund research by the University of Washington to characterize extracellular vesicle (EV) profiles in healthy pregnancies and those complicated by opioid use disorder. The goal is to identify biomarkers in placental EVs and fetal brain/central nervous system EVs that could predict an infant's risk of developing neonatal opioid withdrawal syndrome (NOWS)...
This $6,439,263 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) aims to determine the impact of maternal substance use on maternal immune activation, placental function, and offspring neurobehavioral development. The project will leverage the Healthy Brain and Child Development (HBCD) study to perform maternal immune profiling, placental and cord blood analysis, and novel neuroinflammation imaging on 400...
This federal Project Grant award of $1,499,606.00 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to characterize health outcomes and identify disparities in children born to people with opioid use disorder (OUD) from birth to 5 years of age. The study will utilize data from the Texas Neonatal Care Research Collaborative to:
Examine variation in the diagnosis of neonatal opioid withdrawal syndrome (NOWS) across hospitals and identify...
The National Institute on Drug Abuse (NIDA) awarded a $1,213,117 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University to develop novel compounds that modulate the signaling of the mu opioid receptor (MOR) as potential treatments for pain and opioid use disorder. The research team, in collaboration with scientists at Stanford University and the University of Florida, will synthesize and characterize novel bitopic ligands that target the...
This $180,059 Project Grant award was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research by the Research Institute at Nationwide Children's Hospital (RINCH) to identify positive childhood experiences (PCEs) that can promote optimal developmental outcomes in children with a history of neonatal opioid withdrawal syndrome (NOWS).
The key products and services to be delivered under this 5-year award...
The National Institute on Drug Abuse awarded a $1,076,036 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Pittsburgh to characterize electroencephalography (EEG) signatures and interneuron function within the prefrontal cortex (PFC) following chronic opioid use. The goal is to delineate how PFC interneuron subtypes differentially contribute to PFC circuit oscillations and opioid use behaviors, with the objective of developing novel...
This Project Grant award in the amount of $715,238 was issued on January 15, 2025 by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The project will conduct a large-scale genetic study involving a survey of 500,000 diverse individuals to investigate the genetic basis of opioid-related traits and opioid use disorder (OUD). The research aims to elucidate genetic risk factors across the stages of opioid use, from initial use...